Nektar Therapeutics Common Stock Earnings Dividend

Nektar Therapeutics Common Stock’s revenue fell -9.34% since last year same period to $10.13Mn in the Q2 2026. On a quarterly growth basis, Nektar Therapeutics Common Stock has generated -6.72% fall in its revenue since last 3-months.

Nektar Therapeutics Common Stock’s net profit jumped 2.33% since last year same period to $-40.62Mn in the Q2 2026. On a quarterly growth basis, Nektar Therapeutics Common Stock has generated 9.54% jump in its net profits since last 3-months.

Nektar Therapeutics Common Stock’s net profit margin fell -7.73% since last year same period to -400.97% in the Q2 2026. On a quarterly growth basis, Nektar Therapeutics Common Stock has generated 3.02% jump in its net profit margins since last 3-months.

Nektar Therapeutics Common Stock’s earning per share (EPS) estimates for the current quarter stand at -2.24 - a -8.74% fall from last quarter’s estimates.

Nektar Therapeutics Common Stock’s earning per share (EPS) estimates for the current year stand at -2.24.

Nektar Therapeutics Common Stock’s earning per share (EPS) jumped 58.31% since last year same period to -1.23 in the Q2 2026. This indicates that the Nektar Therapeutics Common Stock has generated 58.31% annual rate of jump in its earning per share (EPS) in the last 4 quarters.